Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Chronic atopic dermatitis (AD) diagnosed according to the Eichenfield modification of Hanifin's and Rajka's (E-HR) criteria at Screening
Disease duration of at least 24 months since diagnosis by any criteria
Documented history of inadequate control of AD by a stable regimen (≥ 4 weeks) of topical corticosteroids, calcineurin inhibitors or biologics, within 6 months of randomization, or inappropriateness of therapy due to side effects or safety risks leading to prior discontinuation
Application of fixed doses of an additive-free, basic bland emollient twice-daily for ≥ 7 days before baseline visit and for the duration of the study
You may not be if
Any major illness/condition or evidence of an unstable clinical condition or local active infection/infectious illness that, in the investigator's judgment, will substantially increase the risk to the participant if he or she participates in the study or interfere with the interpretation of study results
Clinically relevant cardiovascular conditions or pulmonary conditions
High likelihood - based on participant history, and investigator judgement - of requiring rescue therapy in \< 4 weeks prior to randomization
Evidence of acute flare between the Screening and Baseline/ Randomization
Skin lesion(s) and/or pruritus due to conditions other than AD that would interfere with the study specified assessments
Clareo Health | A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis
